Eli Lilly and Company (LLY)
Eli Lilly Has a New Drug That Could Push the Stock Higher
Lilly's Alzheimer's disease drug donanemab could receive FDA approval by year-end. Donanemab would likely be covered by Medicare if approved.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
Eli Lilly's stock is expensive and is trading at around all-time highs. That's thanks to its promising weight-loss and diabetes drugs, Zepbound and Mounjaro.
Lilly files additional lawsuits over US sales of counterfeit Mounjaro
U.S. drugmaker Eli Lilly on Thursday said it was suing six more U.S. medical spas, wellness centers and other entities for selling products claiming to contain tirzepatide, the active ingredient in its popular diabetes drug Mounjaro.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Eli Lilly Stock Analysis: Buy, Hold, or Sell?
Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines.
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
Eli Lilly is developing Mounjaro (tirzepatide) for treating non-alcoholic steatohepatitis. The drugmaker reported positive phase 2 results along those lines earlier this year.
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Eli Lilly's potential Alzheimer's treatment looks closer than ever to approval. It could be a nice addition to the pharmaceutical giant's already-deep portfolio.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
10 Reasons to Buy Eli Lilly Stock Now
The pharmaceutical sector is one that has gone from decades of heavy investment, high growth, and consolidation to a maturing space with a few key players that have more recently provided much more stagnant growth than investors who were around in past decades may remember.
